Double Bond Pharma signs distribution agreement with Belmedpreparaty

Double Bond Pharmaceutical (DBP) has signed an agreement with RUE Belmedpreparaty for distribution of selected dietary supplements on the Scandinavian market. Sales of these products will be managed by the newly established subsidiary of DBP, Drugsson AB.

High quality dietary supplements can substantially improve quality of life for people with impaired uptake of crucial nutrients from the diet and people with increased nutritional needs during a certain situation in life. It is therefore important to be able to introduce high quality products to the market that can match these needs and offer a competitive price to the consumer. Drugsson’s role is to analyze market needs, determine the most appropriate and customer-friendly distribution channels and critically review the products that may be included in Drugsson's distribution portfolio. The products must be of the highest quality standards, be safe and fully comply with up-to-date regulations.

"Belmedpreparaty is the largest pharmaceutical company in Belarus and we are pleased to enter into agreement for distribution of their products," sais Igor Lokot, CEO of DBP. "It is another leap forward for us to build a self-sufficient pharmaceutical corporation".

More about Belmedpreparaty: 

More about DBP:

This information is information that Double Bond Pharmaceutical International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 3 April 2018.

For more info, contact
Igor Lokot, CEO




Follow us on LinkedIn, Facebook and Twitter!

Information on Double Bond Pharmaceutical International AB

DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.



Documents & Links